Cost-Effectiveness versus Cost-Utility Analysis of Interventions for Cancer: Does Adjusting for Health-Related Quality of Life Really Matter?

Value in Health

Volumn 7, Issue 1, 2004, Pages 70-78

  Tengs, Tammy O ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cost effectiveness analysis; Cost utility analysis; Quality of life; Quality adjusted life year; Utility assessment

Indexed keywords

ARTICLE; CANCER; CORRELATION ANALYSIS; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; ECONOMICS; EVALUATION; HEALTH STATUS; HUMAN; NEOPLASM; NONPARAMETRIC TEST; OUTCOMES RESEARCH; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RESOURCE ALLOCATION; UNITED STATES;

EID: 0442293654     PISSN: 10983015     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2004.71246.x     Document Type: Article

References (56)

1. Gold MR, Siegel JE, Russell LB, et al. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press, 1996.
2. Liljas B, Lindgren B. On individual preferences and aggregation in economic evaluation in healthcare. Pharmacoeconomics 2001;19:323-35.
3. Brouwer WBF, Koopmanschap MA. On the economic foundation of CEA: ladies and gentlemen, take your positions. J Health Econ 2000;19:439-59.
4. Treadwell JR. Tests of preferential independence in the QALY model. Med Decis Making 1998;18: 418-28.
5. Garber AM, Phelps CE. Economic foundations of cost-effectiveness analysis. J Health Econ 1997;16: 1-31.
6. Bleichrodt H, Johannesson M. The validity of QALYs: an experimental test of constant proportional tradeoff and utility independence. Med Decis Making 1997;17:21-32.
7. Bleichrodt H. Health utility indices and equity considerations. J Health Econ 1997;16:65-91.
8. Williams A. Economics, QALYs and medical ethics - a health economist's perspective. Health Care Anal 1995;3:221-6.
9. Tengs TO, Yu M, Luistro E. Health-related quality of life after stroke: a comprehensive review. Stroke 2001;32:964-72.
10. Tengs TO, Wallace A. One thousand health-related quality of life estimates. Med Care 2000;38:583-637.
11. Graham JD. Regulatory Health Protection: Analytical Challenges [Internet]. Washington (DC): Office of Management and Budget, 2002 [accessed 2003 Feb 16]. Available from: http://www.white-house.gov/omb/inforeg/april18_speech4.html.
12. NHS Economic Evaluation Database [Internet]. York: University of York, 2001. Available from: http://nhscrd.york.ac.uk/nhsdhp.htm.
13. Earle CC, Chapman RH, Baker CS, et al. Systematic overview of cost-utility assessments in oncology. J Clin Oncol 2000;18:3302-17.
14. Al MJ, Koopmanschap MA, van Enckevort PJ, et al. Cost-effectiveness of lung transplantation in The Netherlands: a scenario analysis. Chest 1998; 113:124-30.
15. Bayoumi AM, Brown AD, Garber AM. Cost-effectiveness of androgen suppression therapies in advanced prostate cancer. J Natl Cancer Inst 2000;92:1731-9.
16. Beemsterboer PM, de Koning HJ, Warmerdam PG, et al. Prediction of the effects and costs of breast-cancer screening in Germany. Int J Cancer 1994; 58:623-8.
17. Bennett CL, Matchar D, McCrory D, et al. Cost-effective models for flutamide for prostate carcinoma patients: are they helpful to policy makers? Cancer 1996;77:1854-61.
18. Coley CM, Barry MJ, Fleming C, et al. Early detection of prostate cancer. II. Estimating the risks, benefits, and costs. Am College Phys Ann Intern Med 1997;126:468-79.
19. Coy P, Schaafsma J, Schofield JA. The cost-effectiveness and cost-utility of high-dose palliative radiotherapy for advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2000;48:1025-33.
20. Cromwell J, Bartosch WJ, Fiore MC, et al. Cost-effectiveness of the clinical practice recommendations in the AHCPR guideline for smoking cessation. JAMA 1997;278:1759-66.
21. de Koning HJ, van Ineveld BM, van Oortmarssen GJ, et al. Breast cancer screening and cost-effectiveness: policy alternatives, quality of life considerations and the possible impact of uncertain factors. Int J Cancer 1991;49:531-7.
22. Desch CE, Hillner BE, Smith TJ, et al. Should the elderly receive chemotherapy for node-negative breast cancer? A cost-effectiveness analysis examining total and active life-expectancy outcomes. J Clin Oncol 1993;11:777-82.
23. Dunscombe P, Samant R, Roberts G. A cost-outcome analysis of adjuvant postmastectomy locoregional radiotherapy in premenopausal node-positive breast cancer patients. Int J Radiat Oncol Biol Phys 2000;48:977-82.
24. Esnaola NF, Lazarides SN, Mentzer SJ, et al. Outcomes and cost-effectiveness of alternative staging strategies for non-small-cell lung cancer. J Clin Oncol 2002;20:263-73.
25. Fiscella K, Franks P. Cost-effectiveness of the transdermal nicotine patch as an adjunct to physicians' smoking cessation counseling. JAMA 1996; 275:1247-51.
26. Freedberg KA, Geller AC, Miller DR, et al. Screening for malignant melanoma: a cost-effectiveness analysis. J Am Acad Dermatol 1999;41:738-45.
27. Glimelius B, Hoffman K, Graf W, et al. Cost-effectiveness of palliative chemotherapy in advanced gastrointestinal cancer. Ann Oncol 1995;6:267-74.
28. Goldie SJ, Freedberg KA, Weinstein MC, et al. Cost effectiveness of human papillomavirus testing to augment cervical cancer screening in women infected with the human immunodeficiency virus. Am J Med 2001;111:140-9.
29. Goldie SJ, Kuntz KM, Weinstein MC, et al. Cost-effectiveness of screening for anal squamous intraepithelial lesions and anal cancer in human immunodeficiency virus-negative homosexual and bisexual men. Am J Med 2000;108:634-41.
30. Goldie SJ, Kuntz KM, Weinstein MC, et al. The clinical effectiveness and cost-effectiveness of screening for anal squamous intraepithelial lesions in homosexual and bisexual HIV-positive men. JAMA 1999;281:1822-9.
31. Goldie SJ, Weinstein MC, Kuntz KM, et al. The costs, clinical benefits, and cost-effectiveness of screening for cervical cancer in HIV-infected women. Ann Intern Med 1999;130:97-107.
32. Goodwin PJ, Feld R, Evans WK, et al. Cost-effectiveness of cancer chemotherapy: an economic evaluation of a randomized trial in small-cell lung cancer. J Clin Oncol 1988;6:1537-47.
33. Grann VR, Sundararajan V, Jacobson JS, et al. Decision analysis of tamoxifen for the prevention of invasive breast cancer. Cancer J Sci Am 2000;6: 169-78.
34. Hall J, Gerard K, Salkeld G, et al. A cost utility analysis of mammography screening in Australia. Soc Sci Med 1992;34:993-1004.
35. Hatziandreu EI, Koplan JP, Weinstein MC, et al. A cost-effectiveness analysis of exercise as a health promotion activity. Am J Pub Health 1988;78: 1417-21.
36. Hillner BE, Kirkwood JM, Atkins MB, et al. Economic analysis of adjuvant interferon alfa-2b in high-risk melanoma based on projections from Eastern Cooperative Oncology Group 1684. J Clin Oncol 1997;15:2351-8.
37. Hillner BE, Smith TJ, Desch CE. Efficacy and cost-effectiveness of autologous bone marrow transplantation in metastatic breast cancer: estimates using decision analysis while awaiting clinical trial results. JAMA 1992;267:2055-61.
38. Hollenbeak CS, Lowe VJ, Stack BC Jr. The cost-effectiveness of fluorodeoxyglucose 18-F positron emission tomography in the NO neck. Cancer 2001;92:2341-8.
39. Hristova L, Hakama M. Effect of screening for cancer in the Nordic countries on deaths, cost and quality of life up to the year 2017. Acta Oncol 1997;36:1-60.
40. Kattan MW, Inoue Y, Giles FJ, et al. Cost-effectiveness of interferon-α and conventional chemotherapy in chronic myelogenous leukemia. Ann Intern Med 1996;125:541-8.
41. Kim JJ, Wright TC, Goldie SJ. Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance. JAMA 2002; 287:2382-90.
42. Lee JH, Glick HA, Hayman JA, et al. Decision-analytic model and cost-effectiveness evaluation of postmastectomy radiation therapy in high-risk premenopausal breast cancer patients. J Clin Oncol 2002;20:2713-25.
43. Marshall D, Simpson KN, Earle CC, et al. Economic decision analysis model of screening for lung cancer. Eur J Cancer 2001;37:1759-67.
44. Mehta M, Noyes W, Craig B, et al. A cost-effectiveness and cost-utility analysis of radiosurgery vs. resection for single-brain metastases. Int J Radiat Oncol Biol Phys 1997;39:445-54.
45. Mooney MM, Mettlin C, Michalek AM, et al. Lifelong screening of patients with intermediate-thickness cutaneous melanoma for asymptomatic pulmonary recurrences: a cost-effectiveness analysis. Cancer 1997;80:1052-64.
46. Ng AK, Kuntz KM, Mauch PM, et al. Costs and effectiveness of staging and treatment options in early-stage Hodgkin's disease. Int J Radiat Oncol Biol Phys 2001;50:979-89.
47. Norum J, Olsen JA. A cost-effectiveness approach to the Norwegian follow-up programme in colorectal cancer. Ann Oncol 1997;8:1081-7.
48. Salzmann P, Kerlikowske K, Phillips K. Cost-effectiveness of extending screening mammography guidelines to include women 40-49 years of age. Ann Intern Med 1997;127:955-65.
49. Smith RD, Hall J, Gurney H, et al. A cost-utility approach to the use of 5-fluorouracil and levami-sole as adjuvant chemotherapy for Dukes' C colonic carcinoma. Med J Aust 1993;158:319-22.
50. Tengs TO, Osgood ND, Chen LL. The cost-effectiveness of intensive national school-based antitobacco education: results from the tobacco policy model. Prev Med 2001;33:558-70.
51. van Enckevort PJ, Ten Vergert EM, Bonsel GJ et al. Technology assessment of the Dutch Lung Transplantation Program. Int J Technol Assess Health Care 1998;14:344-56.
52. Wang LY, Crossett LS, Lowry R, et al. Cost-effectiveness of a school-based tobacco-use prevention program. Arch Pediatr Adolesc Med 2001; 155:1043-50.
53. Hirth RA, Chernew ME, Miller E, et al. Willingness to pay for a quality-adjusted year: in search of a standard. Med Decis Making 2000;20:332-42.
54. Fryback DG, Dasbach EJ, Klein R, et al. The Beaver Dam Health Outcomes Study. Initial catalog of health-state quality factors. Med Decis Making 1993;13:89-102.
55. Fryback DG, Lawrence WF Jr. Dollars may not buy as many QALYs as we think: a problem with defining quality-of-life adjustments. Med Decis Making 1997;17:276-84.
56. Erickson P, Wilson R, Shannon I. Years of healthy life. Healthy People 2000 Statistical Notes. Atlanta (GA): Centers for Disease Control and Prevention, 1995.